Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)

ABSTRACT Introduction Lymphoma is a common malignancy among adolescents and young adults (AYAs) which is generally defined as 15–39 years. Relative to other age groups, lymphoma in AYAs remains understudied with heterogeneous treatment options. Methods We performed a retrospective review of patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Evangeline Y. Wong, Cameron Wellard, Jun Yen Ng, Eliza Chung, Zoe K. McQuilten, Stephen Opat, Erica M. Wood, Dipti Talaulikar
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:eJHaem
Subjects:
Online Access:https://doi.org/10.1002/jha2.1096
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850033872714072064
author Evangeline Y. Wong
Cameron Wellard
Jun Yen Ng
Eliza Chung
Zoe K. McQuilten
Stephen Opat
Erica M. Wood
Dipti Talaulikar
author_facet Evangeline Y. Wong
Cameron Wellard
Jun Yen Ng
Eliza Chung
Zoe K. McQuilten
Stephen Opat
Erica M. Wood
Dipti Talaulikar
author_sort Evangeline Y. Wong
collection DOAJ
description ABSTRACT Introduction Lymphoma is a common malignancy among adolescents and young adults (AYAs) which is generally defined as 15–39 years. Relative to other age groups, lymphoma in AYAs remains understudied with heterogeneous treatment options. Methods We performed a retrospective review of patients aged 18–60 years in the Australasian Lymphoma and Related Diseases Registry (LaRDR) with new diagnoses of the common subtypes of lymphoma in AYAs between January 2016 and April 2023. The subtypes are classic Hodgkin lymphoma (cHL), diffuse large B‐cell lymphoma (DLBCL), primary mediastinal B‐cell lymphoma (PMBCL) and Burkitt lymphoma (BL). Patient demographics, disease characteristics, treatment and outcome data were collected, and comparisons were made between AYAs (18–39 years) and older adults (OAs) (aged 40–60). Results AYAs had higher rates of cHL and PMBCL whereas OAs presented more frequently with DLBCL. AYAs with cHL and PMBCL had higher rates of early‐stage and low‐risk disease than OAs. In contrast, both AYAs and OAs were more likely to present with advanced‐stage DLBCL and BL. AYAs with cHL were more likely to be treated with BEACOPP as compared to OAs who were more commonly treated with ABVD. There was no significant difference in treatment regimens for DLBCL, PMBCL or BL between AYAs and OAs. AYAs with cHL had better overall survival (OS) compared to OAs; specifically, cHL AYAs had better OS and DLBCL AYAs had better progression‐free survival (PFS) and OS compared to OAs. Conclusion The study provides valuable data on patient and disease characteristics, treatments used and outcomes in AYA compared to OA aged 40–60 years. Registry data such as from LaRDR can help improve treatment standardisation and AYA patient outcomes. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission
format Article
id doaj-art-420214cbb56f41a7babaca088db8f856
institution DOAJ
issn 2688-6146
language English
publishDate 2025-02-01
publisher Wiley
record_format Article
series eJHaem
spelling doaj-art-420214cbb56f41a7babaca088db8f8562025-08-20T02:58:01ZengWileyeJHaem2688-61462025-02-0161n/an/a10.1002/jha2.1096Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)Evangeline Y. Wong0Cameron Wellard1Jun Yen Ng2Eliza Chung3Zoe K. McQuilten4Stephen Opat5Erica M. Wood6Dipti Talaulikar7School of Medicine and Psychology College of Health and Medicine Australian National University Canberra AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne Victoria AustraliaSchool of Medicine and Psychology College of Health and Medicine Australian National University Canberra AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne Victoria AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne Victoria AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne Victoria AustraliaSchool of Public Health and Preventive Medicine Monash University Melbourne Victoria AustraliaSchool of Medicine and Psychology College of Health and Medicine Australian National University Canberra AustraliaABSTRACT Introduction Lymphoma is a common malignancy among adolescents and young adults (AYAs) which is generally defined as 15–39 years. Relative to other age groups, lymphoma in AYAs remains understudied with heterogeneous treatment options. Methods We performed a retrospective review of patients aged 18–60 years in the Australasian Lymphoma and Related Diseases Registry (LaRDR) with new diagnoses of the common subtypes of lymphoma in AYAs between January 2016 and April 2023. The subtypes are classic Hodgkin lymphoma (cHL), diffuse large B‐cell lymphoma (DLBCL), primary mediastinal B‐cell lymphoma (PMBCL) and Burkitt lymphoma (BL). Patient demographics, disease characteristics, treatment and outcome data were collected, and comparisons were made between AYAs (18–39 years) and older adults (OAs) (aged 40–60). Results AYAs had higher rates of cHL and PMBCL whereas OAs presented more frequently with DLBCL. AYAs with cHL and PMBCL had higher rates of early‐stage and low‐risk disease than OAs. In contrast, both AYAs and OAs were more likely to present with advanced‐stage DLBCL and BL. AYAs with cHL were more likely to be treated with BEACOPP as compared to OAs who were more commonly treated with ABVD. There was no significant difference in treatment regimens for DLBCL, PMBCL or BL between AYAs and OAs. AYAs with cHL had better overall survival (OS) compared to OAs; specifically, cHL AYAs had better OS and DLBCL AYAs had better progression‐free survival (PFS) and OS compared to OAs. Conclusion The study provides valuable data on patient and disease characteristics, treatments used and outcomes in AYA compared to OA aged 40–60 years. Registry data such as from LaRDR can help improve treatment standardisation and AYA patient outcomes. Trial Registration The authors have confirmed clinical trial registration is not needed for this submissionhttps://doi.org/10.1002/jha2.1096AYABurkitt lymphomaclassic Hodgkin lymphomadiffuse large B‐cell lymphomalymphomaolder adult
spellingShingle Evangeline Y. Wong
Cameron Wellard
Jun Yen Ng
Eliza Chung
Zoe K. McQuilten
Stephen Opat
Erica M. Wood
Dipti Talaulikar
Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
eJHaem
AYA
Burkitt lymphoma
classic Hodgkin lymphoma
diffuse large B‐cell lymphoma
lymphoma
older adult
title Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
title_full Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
title_fullStr Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
title_full_unstemmed Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
title_short Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
title_sort real world data on lymphoma in adolescents and young adults aya report from the lymphoma and related diseases registry lardr
topic AYA
Burkitt lymphoma
classic Hodgkin lymphoma
diffuse large B‐cell lymphoma
lymphoma
older adult
url https://doi.org/10.1002/jha2.1096
work_keys_str_mv AT evangelineywong realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT cameronwellard realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT junyenng realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT elizachung realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT zoekmcquilten realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT stephenopat realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT ericamwood realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr
AT diptitalaulikar realworlddataonlymphomainadolescentsandyoungadultsayareportfromthelymphomaandrelateddiseasesregistrylardr